BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Girgis RR, Baker S, Mao X, Gil R, Javitt DC, Kantrowitz JT, Gu M, Spielman DM, Ojeil N, Xu X, Abi-Dargham A, Shungu DC, Kegeles LS. Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: A pilot in vivo proton magnetic resonance spectroscopy study. Psychiatry Res 2019;275:78-85. [PMID: 30884334 DOI: 10.1016/j.psychres.2019.03.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Yang YS, Maddock RJ, Zhang H, Lee J, Hellemann G, Marder SR, Green MF. N-Acetylcysteine effects on glutathione and glutamate in schizophrenia: A preliminary MRS study. Psychiatry Res Neuroimaging 2022;325:111515. [PMID: 35839558 DOI: 10.1016/j.pscychresns.2022.111515] [Reference Citation Analysis]
2 Deckler E, Ferland M, Brazis S, Mayer MR, Carlson M, Kantrowitz JT. Challenges and Strategies for the Recruitment of Patients With Schizophrenia in a Research Setting. Int J Neuropsychopharmacol 2022;25:924-32. [PMID: 36037521 DOI: 10.1093/ijnp/pyac058] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yamasaki T, Okada M, Hiraishi A, Mori W, Zhang Y, Fujinaga M, Wakizaka H, Kurihara Y, Nengaki N, Zhang MR. Upregulation of Striatal Metabotropic Glutamate Receptor Subtype 1 (mGluR1) in Rats with Excessive Glutamate Release Induced by N-Acetylcysteine. Neurotox Res 2022. [PMID: 34981453 DOI: 10.1007/s12640-021-00449-4] [Reference Citation Analysis]
4 Nakahara T, Tsugawa S, Noda Y, Ueno F, Honda S, Kinjo M, Segawa H, Hondo N, Mori Y, Watanabe H, Nakahara K, Yoshida K, Wada M, Tarumi R, Iwata Y, Plitman E, Moriguchi S, de la Fuente-Sandoval C, Uchida H, Mimura M, Graff-Guerrero A, Nakajima S. Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of (1)H-magnetic resonance spectroscopy studies. Mol Psychiatry 2022;27:744-57. [PMID: 34584230 DOI: 10.1038/s41380-021-01297-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 26.0] [Reference Citation Analysis]
5 Dixon BJ, Kumar J, Danielmeier C. Frontal neural metabolite changes in schizophrenia and their association with cognitive control: A systematic review. Neurosci Biobehav Rev 2021;132:224-47. [PMID: 34864431 DOI: 10.1016/j.neubiorev.2021.11.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
6 Palaniyappan L, Park MTM, Jeon P, Limongi R, Yang K, Sawa A, Théberge J. Is There a Glutathione Centered Redox Dysregulation Subtype of Schizophrenia? Antioxidants (Basel) 2021;10:1703. [PMID: 34829575 DOI: 10.3390/antiox10111703] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
7 Bottino F, Lucignani M, Napolitano A, Dellepiane F, Visconti E, Rossi Espagnet MC, Pasquini L. In Vivo Brain GSH: MRS Methods and Clinical Applications. Antioxidants (Basel) 2021;10:1407. [PMID: 34573039 DOI: 10.3390/antiox10091407] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
8 Coughlin JM, Yang K, Marsman A, Pradhan S, Wang M, Ward RE, Bonekamp S, Ambinder EB, Higgs CP, Kim PK, Edwards JA, Varvaris M, Wang H, Posporelis S, Ma S, Tsujimura T, Edden RAE, Pomper MG, Sedlak TW, Fournier M, Schretlen DJ, Cascella NG, Barker PB, Sawa A. A multimodal approach to studying the relationship between peripheral glutathione, brain glutamate, and cognition in health and in schizophrenia. Mol Psychiatry 2021;26:3502-11. [PMID: 33077854 DOI: 10.1038/s41380-020-00901-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
9 Aoyama K. Glutathione in the Brain. Int J Mol Sci 2021;22:5010. [PMID: 34065042 DOI: 10.3390/ijms22095010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 15.0] [Reference Citation Analysis]
10 Egerton A. The potential of (1)H-MRS in CNS drug development. Psychopharmacology (Berl) 2021;238:1241-54. [PMID: 31486875 DOI: 10.1007/s00213-019-05344-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
11 Yolland CO, Hanratty D, Neill E, Rossell SL, Berk M, Dean OM, Castle DJ, Tan EJ, Phillipou A, Harris AW, Barreiros AR, Hansen A, Siskind D. Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia. Aust N Z J Psychiatry 2020;54:453-66. [PMID: 31826654 DOI: 10.1177/0004867419893439] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 14.3] [Reference Citation Analysis]
12 Kathuria A, Lopez-Lengowski K, Watmuff B, McPhie D, Cohen BM, Karmacharya R. Synaptic deficits in iPSC-derived cortical interneurons in schizophrenia are mediated by NLGN2 and rescued by N-acetylcysteine. Transl Psychiatry 2019;9:321. [PMID: 31780643 DOI: 10.1038/s41398-019-0660-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
13 Reyes-Madrigal F, León-Ortiz P, Mao X, Mora-Durán R, Shungu DC, de la Fuente-Sandoval C. Striatal Glutathione in First-episode Psychosis Patients Measured In Vivo with Proton Magnetic Resonance Spectroscopy. Arch Med Res 2019;50:207-13. [PMID: 31499481 DOI: 10.1016/j.arcmed.2019.08.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]